| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Address correspondence and reprint request to Dr. Marinos C. Dalakas, Chief, Neuromuscular Diseases Section, NINDS, NIH, Building 10, Room 4N248, 10 Center Dr. MSC 1382, Bethesda, MD 20892-1382.
OBJECTIVE: To investigate whether the combination of intravenous immunoglobulin (IVIg) with prednisone improves muscle strength and alters endomysial inflammation in patients with sporadic inclusion body myositis (s-IBM).
BACKGROUND: In a previous controlled trial in s-IBM, IVIg did not significantly improve strength in spite of modest benefits in some muscle groups. The possibility that prednisone may have a synergistic effect with IVIg prompted another controlled trial.
METHODS: Thirty-six patients with biopsy-proven IBM were randomized to receive IVIg or placebo monthly for 3 months. Before infusions, all patients were started on high-dose prednisone for 3 months. Primary outcome measures were differences in the 1) Quantitative Muscle Strength (QMT) testing; and 2) modified Medical Research Council (MRC) scores, between the patients randomized to IVIg + prednisone compared with those randomized to placebo + prednisone. Repeated open muscle biopsies were performed at random in 24 patients to determine changes in the number of autoinvasive T cells and necrotic muscle fibers.
RESULTS: Nineteen patients were randomized to IVIg + prednisone and 17 to placebo + prednisone. No significant change was noted in muscle strength, assessed by QMT and MRC, from baseline to the 2nd, 3rd, or 4th month after treatment between the two groups. The number of necrotic fibers was reduced in the IVIg randomized group (p < 0.01), and the mean number of CD2+ cells was significantly decreased in both groups (p < 0.0001), denoting a steroid effect.
CONCLUSION: IVIg combined with prednisone for a 3-month period was not effective in IBM. Endomysial inflammation was significantly reduced after treatment, but the reduction was not of clinical significance.
This article has been cited by other articles:
|
|
 |
|
  M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Greenberg Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications Neurology, November 20, 2007; 69(21): 2008 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Helmers, M. Dastmalchi, H. Alexanderson, I. Nennesmo, M. Esbjornsson, B. Lindvall, and I. E Lundberg Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies Ann Rheum Dis, October 1, 2007; 66(10): 1276 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Gurcan and A R. Ahmed Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders Ann. Pharmacother., May 1, 2007; 41(5): 812 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dimitri, O. Benveniste, O. Dubourg, T. Maisonobe, B. Eymard, Z. Amoura, L. Jean, K. Tiev, J.-C. Piette, D. Klatzmann, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis Brain, April 1, 2006; 129(4): 986 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barohn, L. Herbelin, J. T. Kissel, W. King, A. L. McVey, D. S. Saperstein, and J. R. Mendell Pilot trial of etanercept in the treatment of inclusion-body myositis Neurology, January 24, 2006; 66(1_suppl_1): S123 - S124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Raju and M. C. Dalakas Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes Brain, August 1, 2005; 128(8): 1887 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Ranque-Francois, T Maisonobe, E Dion, J-C Piette, M-P Chauveheid, Z Amoura, and T Papo Familial inflammatory inclusion body myositis Ann Rheum Dis, April 1, 2005; 64(4): 634 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases JAMA, May 19, 2004; 291(19): 2367 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schmidt, G. Rakocevic, R. Raju, and M. C. Dalakas Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity Brain, May 1, 2004; 127(5): 1182 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lindberg, E. Trysberg, A. Tarkowski, and A. Oldfors Anti-T-lymphocyte globulin treatment in inclusion body myositis: A randomized pilot study Neurology, July 22, 2003; 61(2): 260 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hilton-Jones DIAGNOSIS AND TREATMENT OF INFLAMMATORY MUSCLE DISEASES J. Neurol. Neurosurg. Psychiatry, June 1, 2003; 74(90002): ii25 - 31. [Full Text] [PDF]
|
|
|
|
|
|
S. B. Rutkove, R. A. Parker, R. A. Nardin, C. E. Connolly, K. J. Felice, and E. M. Raynor A pilot randomized trial of oxandrolone in inclusion body myositis Neurology, April 9, 2002; 58(7): 1081 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cherin, S. Pelletier, A. Teixeira, P. Laforet, A. Simon, S. Herson, and B. Eymard Intravenous immunoglobulin for dysphagia of inclusion body myositis Neurology, January 22, 2002; 58(2): 326 - 326. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
